<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906269</url>
  </required_header>
  <id_info>
    <org_study_id>STAF001982HU</org_study_id>
    <nct_id>NCT00906269</nct_id>
  </id_info>
  <brief_title>Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer</brief_title>
  <acronym>HBOT</acronym>
  <official_title>Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if adding hyperbaric oxygen therapy, a therapy that
      delivers oxygen under slight pressure, to a drug treatment of PDE5I (such as Viagra, Levitra,
      Cialis)for men following surgery for prostate cancer will result in more men being able to
      continue to have erections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is the most common non-skin malignancy in men in the United States, with
      approximately 232,000 diagnoses of adenocarcinoma projected for 2005. More than 150,000 of
      these men are treated with radical prostatectomy. Common sequelae following successful NSRRP
      (nerve-sparing radical retropubic prostatectomy)include urinary incontinence and sexual
      dysfunction. Recent advances in surgery technique and treatment have been made but in spite
      of aggressive management, recovery of sexual function is incomplete with fewer than one-fifth
      reporting return to baseline. The etiology of erectile dysfunction following radical
      prostatectomy results most probably from local surgical trauma and neurapraxia, which leads
      to corpus cavernosal hypoxemia in the post-NSRRP period. This hypoxemia is believed to impact
      negatively on the health and maintenance of the smooth muscle cells within the corpus
      cavernosum. Hyperbaric oxygen therapy (HBO2T) is a unique modality that is able to provide
      oxygen delivery to tissues that have been damaged by traumatic injury.

      Hypothesis: The addition of post-NSRRP hyperbaric oxygen therapy (HBO2T) to a treatment of
      phosphodiesterase type 5 inhibitor (PDE5I) will reduce the incidence of erectile dysfunction
      (ED) and urinary incontinence when measured at 1, 3, 6, 12 and 18 months post-NSRRP for Stage
      I prostate cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile function domain of Internation Index of Erectile Function (IIEF)</measure>
    <time_frame>1, 3, 6, 12, and 18 months post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical or biochemical recurrence of cancer</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Impotence</condition>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil therapy plus post-NSRRP HBO2T</intervention_name>
    <description>Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil therapy plus sham post-NSRRP HBO2T</intervention_name>
    <description>Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  age 40-69

          -  diagnosis of Stage I prostate cancer

          -  bilateral NSRRP as primary treatment

          -  sexual potency prior to surgery

        Exclusion Criteria:

          -  COPD, CHF, diabetes mellitus

          -  known inability to tolerate PDE5I

          -  confinement anxiety/claustrophobia

          -  planned adjuvant or neo-adjuvant therapy

          -  patients taking alpha blockers or nitrates

          -  patients with retinitis pigmentosa
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Graydon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alison Champagne, BS</last_name>
    <phone>860-545-6049</phone>
    <email>achampa@harthosp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilene Staff, PhD</last_name>
    <phone>860-545-0178</phone>
    <email>IStaff@harthosp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Graydon, MD</last_name>
      <phone>860-947-8500</phone>
      <email>jgraydo@harthosp.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.harthosp.org</url>
    <description>Hartford Hospital Home Page</description>
  </link>
  <reference>
    <citation>Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005 Jun 1;293(21):2648-53.</citation>
    <PMID>15928287</PMID>
  </reference>
  <reference>
    <citation>Mulhall JP, Graydon RJ. The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int J Impot Res. 1996 Jun;8(2):91-4.</citation>
    <PMID>8858398</PMID>
  </reference>
  <reference>
    <citation>Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982 Sep;128(3):492-7.</citation>
    <PMID>7120554</PMID>
  </reference>
  <reference>
    <citation>Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-30.</citation>
    <PMID>9187685</PMID>
  </reference>
  <reference>
    <citation>Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000 Dec 20;56(6):899-905.</citation>
    <PMID>11113727</PMID>
  </reference>
  <reference>
    <citation>Feldmeier, J.J.,Chairman and Editor. Hyperbaric Oxygen 2003: Indications and Results. The Hyperbaric Oxygen Therapy Committee Report . Kensington, MD: Undersea and Hyperbaric Medicine Society, 2003.</citation>
  </reference>
  <reference>
    <citation>Feldmeier JJ. Hyperbaric oxygen: does it have a cancer causing or growth enhancing effect? In: Proceeding of the Concensus Conference sponsored by the European Society for Therapeutic Radiology and Oncology and the European Committee for Hyperbaric Medicine. Portugal 2001: 129-146</citation>
  </reference>
  <results_reference>
    <citation>Link RE, Su LM, Sullivan W, Bhayani SB, Pavlovich CP. Health related quality of life before and after laparoscopic radical prostatectomy. J Urol. 2005 Jan;173(1):175-9; discussion 179.</citation>
    <PMID>15592069</PMID>
  </results_reference>
  <results_reference>
    <citation>Zamboni WA, Brown RE, Roth AC, Mathur A, Stephenson LL. Functional evaluation of peripheral-nerve repair and the effect of hyperbaric oxygen. J Reconstr Microsurg. 1995 Jan;11(1):27-9; discussion 29-30.</citation>
    <PMID>7714876</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004 Sep;172(3):920-2. Review.</citation>
    <PMID>15310998</PMID>
  </results_reference>
  <results_reference>
    <citation>Lowentritt BH, Scardino PT, Miles BJ, Orejuela FJ, Schatte EC, Slawin KM, Elliott SP, Kim ED. Sildenafil citrate after radical retropubic prostatectomy. J Urol. 1999 Nov;162(5):1614-7.</citation>
    <PMID>10524880</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol. 2004 Feb;171(2 Pt 1):771-4.</citation>
    <PMID>14713808</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>impotence</keyword>
  <keyword>prostatic neoplasms</keyword>
  <keyword>hyperbaric oxygenation</keyword>
  <keyword>Phosphodiesterase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

